Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity-Reference-Cited by-同舟云学术

Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity

Published:2024-09-12 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chang Yingjie¹,Guo Huahui²³,Li Xue¹,Zong Liangyi²³,Wei Jiale⁴,Li Zhihai⁴^ORCID,Luo Cheng⁴⁵^ORCID,Yang Xinying¹,Fang Hao¹^ORCID,Kong Xiangqian²³^ORCID,Hou Xuben¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Wenhuaxi Road, Jinan 250012, China

2. State Key Laboratory of Respiratory Disease, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China

3. University of Chinese Academy of Sciences (UCAS), 19 Yuquan Road, Beijing 100049, China

4. School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China

5. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

Funder

National Key Research and Development Program of China

Basic and Applied Basic Research Foundation of Guangdong Province

Taishan Scholar Project of Shandong Province

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

Shandong University

National Natural Science Foundation of China

Lingang Laboratory

Pearl River Talents Plan

Shandong Provincial Youth Innovation Team Development Program

Publisher

American Chemical Society (ACS)